ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business context and reporting period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated August 17, 2021, with the report signed on August 18, 2021. The company is a Delaware corporation whose common stock trades on The Nasdaq Global Select Market under the symbol ORIC. This filing reports an event under Item 8.01, “Other Events.”
Key financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
The filing reports the conclusion of an SEC investigation involving Dominic Piscitelli, ORIC’s Chief Financial Officer, in his personal capacity. In March 2020, Mr. Piscitelli received an SEC subpoena for documents and information concerning trading in securities of certain other companies unrelated to ORIC.
On August 17, 2021, the SEC notified Mr. Piscitelli that it had concluded its investigation as to him without recommending further action at that time. The filing does not report any investigation into ORIC or any financial impact.
Guidance, outlook, risks, contingencies, and unusual items
- The SEC investigation related to securities trading at other companies and was not described as related to ORIC.
- The SEC concluded its investigation of Mr. Piscitelli without recommending further action at that time.
- The filing provides no earnings guidance, operating outlook, contingency estimate, or additional risk disclosure.
Investor verification points
- Verify that the SEC matter concerned Mr. Piscitelli personally and securities of companies unrelated to ORIC.
- Verify the August 17, 2021 conclusion of the investigation and the absence of a recommendation for further action at that time.
- Review subsequent filings for any later developments, qualifications, or disclosures concerning the matter.